Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Analysis of drug review performance by division finds Cardiovascular & Renal Drugs Division to occupy the lower end of the spectrum. Staffing appears to be a vital component of review performance, giving weight to the researchers’ warning of impending wholesale staff turnover.

You may also be interested in...



BIO Survey Seeks To Uncover Inconsistencies In Review Divisions

The trade group will ask members to characterize their pre-clinical and clinical stage interactions with FDA in an effort to find potential efficiencies as well as inform upcoming legislation, including PDUFA VI.

Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices

FDA’s drugs center should identify “best practices” in oncology and antiviral drug reviews that could be applied by less efficient review divisions, such as cardio/renal and neurology, authors of a Manhattan Institute report say.

Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High

With 45 new molecular entities and novel biologics cleared in 2012, FDA approvals have reached a level not seen since the mid-1990s, the golden age of modern medicine. The group reflects a boom in oncology; other drug development trends like orphan diseases and personalized medicine held steady. Big pharma contributed just over a third of the 2012 class, with Pfizer regaining the lead with five novel approvals.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel